



Nordic Thoracic Oncology Group



11th Nordic Lung Cancer Symposium 2014
Copenhagen, Denmark
January 17-19, 2014

Organizing Committee:
Jens Benn Sørensen (DK) Signe Friesland (S)
Odd Terje Brustugun (N) Eeva-Maija Nieminen (SF)

Conference venue:
Scandic Copenhagen Conference Center, Vester Søgade 6, 1601 Copenhagen

Programme

Friday, Jan. 17		
08.30 – 08.45	Wellcome Jens Benn Sørensen (Denmark, DK), Eeva-Maija Nieminen (Finland, FI), Odd Terje Brustugun (Norway, NO), Signe Friesland (Sweden, SE)	
08.45 – 9.45	Diagnosis and Staging Chairman: Eeva-Maija Nieminen (SF)	
	Current position of Radiological Screening for lung cancer	Jesper Holst Petersen (DK)
	Minimal tissue requirements and methods to reach a subtype diagnosis and customize treatments	Kaisa Salmenkivi (FI)
	Advances by use of PET/CT fused imaging in staging procedures	Barbara Malene Fischer (DK)
	National Indicator Project and prognostic improvements, the Danish experience	Erik Jakobsen (DK)
09.50 – 10.15	Coffee Break	
10.15 – 12.00	Treatment of Early NSCLC Chairmen: Hans Kristian Pilegaard (DK), Odd Terje Brustugun (NO)	
	Robotic assisted VATS lobectomy	Jari Räsänen (FI)
	New frontiers in surgery for T4 tumors and superior sulcus	Per Bergman (SE)
	Quality of life after resection of NSCLC	Ilkka Ilonen (FI)
	Stereotactic Radiotherapy in lung cancer	Rolf Lewensohn (SE)
	Will there be a role for customizing adjuvant treatment?	Frances Shepherd (CAN)
	Should NSCLC stage IB receive adjuvant treatment?	Sandra Wallerek (DK)



Nordic Thoracic Oncology Group



Friday, Jan. 17		
12.00 – 13.00	Lunch Buffet	
13.00 – 14.30	Satellite Symposium: “Customizing treatment in advanced NSCLC” Sponsored by Eli Lilly, Astra-Zeneca, and Pfizer	
14.30 – 14.50	Coffee Break	
14.50 – 16.15	Locally Advanced NSCLC Chairman: Signe Friesland (SE)	
	Does surgery benefit in N2 disease? The NTOG N2 study	Jens Benn Sørensen (DK)
	Principles of modern Thoracic Radiotherapy	Einar Waldeland (NO)
	Concomitant chemo-radiotherapy: Which drugs?	Olfred Hansen (DK)
	Does PORT benefit in N2/N3 disease?	Francoise Mornex (F)
	Improving survival in SCLC with radiotherapy	Bjørn Henning Grønberg (NO)
16.15 - 16.40	Coffee Break	
16.40 - 17.30	Satellite Symposium: Sponsored by Boehringer-Ingelheim	
18.00 – 19.30	Wellcome reception	
	Dinner on own	
Saturday, Jan. 18		
08.30 – 10.00	Malignant Mesothelioma Chairman: Henrik Riska (FI)	
	Surgery in Mesothelioma: Extrapleural Pneumonectomy (EPP) or Pleurectomy/Decortication (P/D)?	Jesper Ravn (DK)
	Predictive and prognostic biomarkers in MPM	Katalina Dobra (SE)
	Epidemiologic trends in MPM: Norway	Åslaug Helland (NO)
	Epidemiologic trends in MPM: Denmark	Øyvind Omland (DK)
10.00 – 10.20	Coffee break	
10.20 – 12.00	Targeting signaling pathways Chairman: Signe Friesland (SE)	
	Detecting oncogenic driver mutations in Adenocarcinoma and squamous cell carcinomas	Fredrik Enlund (SE)
	EGFR mutations in an unselected community based kaukasian population	Birgit Guldhammer Skov (DK)



Nordic Thoracic Oncology Group



Saturday, Jan. 18	Treatment in EGFR mutated NSCLC and mechanisms of resistance	Jussi Koivunen (SF)
	Detecting oncogenic driver mutations in blood samples	Peter Meldgaard (DK)
	Treatment of ALK- and ROS-1 translocated NSCLC and mechanisms of resistance	Bengt Halberg (SE)
	Is B-raf ready for routine clinical use?	Odd Terje Brustugun (NO)
12.00 – 13.00	Lunch Buffet	
13.00 – 13.45	Satellite Symposium: Sponsored by Roche	
13.50 – 14.30	Immunomodulatory treatments Chairman: Paal Brunsvig (NO)	
	Anti PD-1 treatment	Luigi de Petris (SE)
	Other immunomodulatory strategies	Jon Amund Kyte (NO)
14.30 – 14.50	Coffee Break	
14.50-16.15	Break-out sessions A. Targeted treatment in the adjuvant setting of NSCLC. (Chair: Mikael Johansson (SE)) B. Stereotactic radiotherapy (Chair: Åslaug Helland (NO)) C. Screening (Chair: Asger Dirksen (DK)) D. Biomarkers and translational research (Simon Ekman (SE))	
19.00	Conference Dinner (advance registration before JAN 15 mandatory)	
Sunday, Jan. 19		
08.30 – 9.30	Feedback from break-out sessions (15 minutes for each group, Q and A)	
09.45 – 12.30	Treatments in Advanced NSCLC Chairmen: Jens Benn Sørensen (DK), Øyvind Fløten (NO)	
	First-line treatment strategies in the absence of targetable driver mutations	Robert Pirker (A)
	Predictive biomarkers for chemotherapy	Jan Nyrop Jakobsen (DK)
	Targeting angiogenesis in NSCLC	Arnauld Scherpereel (F)
10.30 – 10.50	Coffee Break	
	Who are candidates for maintenance treatments and who are not?	Anders Vikstrøm (SE)
	Future need for re-biopsies before changing medical antineoplastic treatments	Antti Jekunen (FI)



Nordic Thoracic Oncology Group



<i>Sunday, Jan. 19</i>	Skeletal related events: Role of denosumab and zeledronic acid	Stein Sundstrøm (NO)
	Treatment of Thoracal Neuroendocrine Tumors: Current experience	Seppo Langer (DK)
12.30 – 12.45	Adjourn	
12.45	Lunch Buffet	
	Departure	

We thanks the sponsors of the 11th Nordic Lung Cancer Symposium

